Moderna's shares surged 131% after the biotech scored a Phase 3 trial win against the standard of care for cancer. The stock rally left short sellers with $4.8 billion in losses.
This item was indexed from its published source and tied to the entity records it names. The Counterparty reports what the market says and who it says it about; it does not rewrite the original report. Read the source for the full account.